1 step closer to green chemistry and improved pharmaceuticalsJune 25, 2008Researchers at the University of Copenhagen, Denmark, solve an important piece of the puzzle behind how proteins are shaped Proteins are the workhorses of our cells. They help to digest our food, are at the core of our immune system, and literally shape our body from top to toe. Proteins also play an important role in biotechnology in the form of enzymes, which are important in the creation of anything from pharmaceuticals to bread, washing powder and much more. Their possibilities are virtually without limit. To take advantage of their great potential, a detailed understanding of the three-dimensional shape of proteins is necessary. This is normally achieved through a complicated and expensive process in the laboratory. For years, researchers have tried to replace these experiments by computer simulations. Now, two researchers at the Department of Biology at the University of Copenhagen, Assoc. professor Thomas Hamelryck and PhD-student Wouter Boomsma, have solved an important part of the problem of modeling the three dimensional shape of proteins. After 5 years of research, they have succeeded in developing a mathematical model that incorporates knowledge from physics, probability theory and geometry to describe the structure of proteins. This has given protein researchers a valuable new tool for the improved understanding of the shape and function of proteins. "Each individual protein has its own unique chemical composition, consisting of 20 different amino acids in various different combinations. There are an endless number of such combinations, each giving rise to its own shape. We have developed a simple mathematical model that captures these different shapes. This means that it will become easier for industry and researchers to use proteins to achieve their goals. For example in the development of green chemistry, where dangerous chemicals are replaced with protein-based products, which are more environment friendly", says Thomas Hamelryck. Thomas also points to the fact that their computer model can have a great impact on the pharmaceutical industry. "Proteins and illness are highly related, and most pharmaceuticals are targeted at proteins in our body. As we increase our knowledge of these proteins, the chance of finding more efficient pharmaceuticals for illnesses such as cancer, diabetes and AIDS are greatly enhanced", Thomas continues. The two researchers at the University of Copenhagen are currently collaborating closely with partners in the biotech industry to explore these possibilities. University of Copenhagen |
|||||||||||||||||||||
| Related Pharmaceuticals Current Events and Pharmaceuticals News Articles Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. Sweet -- sugared polymer a new weapon against allergies and asthma Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks. Viagra for women? Drug developed as antidepressant effective in treating low libido Pooled results from three separate clinical trials of flibanserin, a drug originally created as an antidepressant, show it is effective in treating women with acquired hypoactive sexual desire disorder. These trials were the first ever to test a therapy that works at the level of the brain to enhance libido in women reporting low sexual desire. Approved lymphoma drug shows promise in early tests against bone cancer A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. Researchers identify drug candidate for treating spinal muscular atrophy A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants. UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. Clinical tests begin on medication to correct Fragile X defect NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. TGen seeks emergency FDA approval of new swine flu test The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus. Triple-Combo Drug Shows Promise Against Antiviral-Resistant Swine Flu, UAB Researcher Says An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases. Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). More Pharmaceuticals Current Events and Pharmaceuticals News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||